Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Update of Swatch Study: Selinxor Combined with Lenalidomide and Rituximab (R2) in Adults with Diffuse Large B Cell Lymphoma (DLBCL) and Indolent Non-Hodgkin's Lymphoma (iNHL)

Li Wang, Zhiming Li, Lina Zhang, Liling Zhang, Jay Mei, Wei Li Zhao

Blood (2023) 142 (Supplement 1): 6235.

https://doi.org/10.1182/blood-2023-180535

Published: 2023

Journal Articles

Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment

Xiwen Tong, Shuai Su, Bin Xu, Xiaojian Zhu, Yizhou Peng, Jin Jie, Xia Mao, Min Xiao, Jay Mei, Donghua Zhang

Blood (2023) 142 (Supplement 1): 5837.

https://doi.org/10.1182/blood-2023-186006

Published: 2023

Journal Articles

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Zhiming Li, Hang Yang, Yanxue Yin, Yajun Li, Xue Gao, Peng Sun, Yu Wang, Lu Zhang, Hui Zhou, Keshu Zhou, Jay Mei

Blood (2023) 142 (Supplement 1): 6240.

https://doi.org/10.1182/blood-2023-181503

Published: 2023

Journal Articles

Selinexor Combined Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma with Extramedullary Disease(EMD) or High-Risk Cytogenetics

Yuping Zhong, Xiaoxia Chu, Junqing Xu, Xiaoqian Liu, Chenglu Yuan, Xia Zhou, Hongying Wu, Yayun Wang, Shuyuan Yu, Hongyan Zhang, Jay Mei

Blood (2023) 142 (Supplement 1): 6620.

https://doi.org/10.1182/blood-2023-172937

Published: 2023

Journal Articles

Efficacy and Safety of Selinexor-Based Combination Therapy in CNS Lymphoma: A Retrospective Experience

Li Li, Yan Ma, Xiaobo Wang, Zhiming Li, Zhiguang Lin, Qi Zhang, Jay Mei, Jingjing Ma, Xin Gao, Hui Kang, Zhijia Zhao, Hang Yang, Qing Li, Mengxue Zhang, Yingbo Zhou, Bobin Chen

Blood (2023) 142 (Supplement 1): 6301.

https://doi.org/10.1182/blood-2023-184682

Published: 2023

Journal Articles

Preliminary Results from the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Chunyan Sun, Fei Zhao, Junying Li, Chun Zhang, Weiming Li, Hui Cheng, Huili Cai, Bin Chen, Jingming Guo, Jay Mei, Yu Hu

Blood (2022) 140 (Supplement 1): 12613.

https://doi.org/10.1182/blood-2022-169053

Published: 2022

Journal Articles

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

Xin Du, MD, Jie Jin, MD, Zhen Cai, MD, Fangping Chen, MD, Dao-bin Zhou, MD, Li Yu, MD, Xiaoyan Ke, MD PhD, Xiao Li, MD PhD, Depei Wu, MD, Fanyi Meng, MD, Dena DeMarco, Jingshan Zhang, PhD, Jay Mei, MD, Jian Hou, MD PhD

Blood (2014) 124 (21): 5737.

https://doi.org/10.1182/blood.V124.21.5737.5737

Published: 2014

Journal Articles

The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety

Jie Jin, MD, Xin Du, MD, Zhen Cai, MD, Fangping Chen, MD, Dao-bin Zhou, MD, Li Yu, MD, Xiao Li, MD, PhD, Depei Wu, MD, Fanyi Meng, MD, Huisheng Ai, MMed, Jianmin Wang, MD, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Jay Mei, MD, Jian Hou, MD, PhD

Blood (2013) 122 (21): 3227.

https://doi.org/10.1182/blood.V122.21.3227.3227

Published: 2013

Journal Articles

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Andreas Bühler, Clemens Wendtner, MD, Michael Hallek, Thomas J. Kipps, MD, PhD, Laura Rassenti, PhD, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, MD, Stephanie A. Gregory, Matt Kalaycio, MD, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1638.

https://doi.org/10.1182/blood.V122.21.1638.1638

Published: 2013

Journal Articles

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292

Blood (2013) 122 (21): 4169.

https://doi.org/10.1182/blood.V122.21.4169.4169

Published: 2013

Journal Articles

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD, PhD, Wael A. Harb, MD, Brian T. Hill, MD, PhD, Janice Gabrilove, MD, Jeff P. Sharman, MD, Marshall T. Schreeder, MD, MPH, Paul M. Barr, MD, James M. Foran, MD, Thomas P. Miller, MD, Jan A. Burger, MD, PhD, Kevin R. Kelly, MD, PhD, Daruka Mahadevan, MD, PhD, Shuo Ma, MD, PhD, Evelyn Barnett, Jeffrey Marine, Pilar Nava-Parada, Ada Azaryan, Jay Mei, MD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 1630.

https://doi.org/10.1182/blood.V122.21.1630.1630

Published: 2013

Journal Articles

Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis

Dao-bin Zhou, MD, Li Yu, MD, Xin Du, MD, Jie Jin, MD, Zhen Cai, MD, Fangping Chen, MD, Xiao Li, MD, PhD, Depei Wu, MD, Fanyi Meng, MD, Huisheng Ai, MMed, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Jay Mei, MD, Jianmin Wang, MD, Jian Hou, MD, PhD

Blood (2013) 122 (21): 5374.

https://doi.org/10.1182/blood.V122.21.5374.5374

Published: 2013

Journal Articles

A Multi-Center, Open-Label Phase II Study of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma - the MM-021 Trial

Jian Hou, MD, PhD, Jie Jin, MD, Zhen Cai, Fangping Chen, Li Yu, Dao-bin Zhou, MD, Xiao Li, MD, PhD, Xiaoyan Ke, MD, PhD, Depei Wu, MD, Huisheng Ai, Fanyi Meng, MD, Jianmin Wang, Jay Mei, MD, PhD, Jingshan Zhang, PhD, Honeylet Wortman-Vayn, Xin Du, PhD

Blood (2012) 120 (21): 1864.

https://doi.org/10.1182/blood.V120.21.1864.1864

Published: 2012

Journal Articles

Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Clemens Wendtner, MD, Michael Hallek, MD, Graeme Fraser, Anne-Sophie Michallet, MD, PhD, Peter Hillmen, Jan Duerig, Stephanie A. Gregory, MD, Matt Kalaycio, MD, Stephan Stilgenbauer, MD, Andreas Buehler, Thomas J. Kipps, MD, PhD, Brendan Purse, Jennie Zhang, Jay Mei, MD, PhD, Asher Chanan-Khan, MD

Blood (2012) 120 (21): 3925.

https://doi.org/10.1182/blood.V120.21.3925.3925

Published: 2012

Journal Articles

Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial

Nianhang Chen, PhD, Dao-bin Zhou, MD, Li Yu, Jay Mei, MD, PhD, Liangang Liu, Xiaomin Wang, Honeylet Wortman-Vayn, Jian Hou, MD, PhD

Blood (2012) 120 (21): 5046.

https://doi.org/10.1182/blood.V120.21.5046.5046

Published: 2012

Journal Articles

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

Clemens Wendtner, MD, Graeme Fraser, Stuart L. Goldberg, MD, Adrian JC Bloor, PhD, FRCP, FRCPath, Stephan Stilgenbauer, Florence Cymbalista, Thomas Kipps, Brendan Purse, Jennie Zhang, Jay Mei, MD, PhD, Asher Chanan-Khan

Blood (2011) 118 (21): 2859.

https://doi.org/10.1182/blood.V118.21.2859.2859

Published: 2011

Journal Articles

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,

Meletios Athanasios Dimopoulos, MD, Antonio Palumbo, MD, Roman Hajek, MD, PhD, Martin Kropff, MD, Maria Teresa Petrucci, MD, Philip Lewis, PhD, Stefanie Millar, Jingshan Zhang, PhD, Jay Mei, MD, PhD, Michel Delforge, MD, PhD

Blood (2011) 118 (21): 3988.

https://doi.org/10.1182/blood.V118.21.3988.3988

Published: 2011

Journal Articles

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015

Blood (2011) 118 (21): 475.

https://doi.org/10.1182/blood.V118.21.475.475

Published: 2011

Journal Articles

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression

Meletios Athanasios Dimopoulos, MD, Michel Delforge, MD, PhD, Roman Hajek, MD, PhD, Martin Kropff, MD, Maria Teresa Petrucci, MD, Philip Lewis, PhD, Stefanie Millar, Jingshan Zhang, PhD, Jay Mei, MD, PhD, Antonio Palumbo, MD

Blood (2011) 118 (21): 3157.

https://doi.org/10.1182/blood.V118.21.3157.3157

Published: 2011

Journal Articles

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.

Antonio Palumbo, Meletios A. Dimopoulos, Michel Delforge, Martin Kropff, Robin Foa, Zhinuan Yu, Lindsay Herbein, Jay Mei, Christian Jacques, John Catalano

Blood (2009) 114 (22): 613.

https://doi.org/10.1182/blood.V114.22.613.613

Published: 2009

NARROW

Update of Swatch Study: Selinxor Combined with Lenalidomide and Rituximab (R2) in Adults with Diffuse Large B Cell Lymphoma (DLBCL) and Indolent Non-Hodgkin's Lymphoma (iNHL)

Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Selinexor Combined Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma with Extramedullary Disease(EMD) or High-Risk Cytogenetics

Efficacy and Safety of Selinexor-Based Combination Therapy in CNS Lymphoma: A Retrospective Experience

Preliminary Results from the Launch Study-a Multicenter, Open-Label Study of Selinexor, Dexamethasone and Chemotherapy Drugs in Relapsed/ Refractory Multiple Myeloma

Long-Term Use of Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Chinese Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): MM-024 Expanded Access Program (EAP)

The MM-021 Trial Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma: Impact Of Prior Therapies On Efficacy and Safety

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis

A Multi-Center, Open-Label Phase II Study of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma - the MM-021 Trial

Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Pharmacokinetics (PK) of Lenalidomide When Administered Alone or in Combination with Dexamethasone in Chinese Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): The MM-021 Trial

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only